South Delhi Pharma, New Delhi, India
EYLEA® (aflibercept) Injection, for Intravitreal Use
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.
Facts of Eylea (aflibercept)
EYLEA® (aflibercept) Injection, for Intravitreal Use
Generic Name: aflibercept
Initial U.S. Approval: 2011
• Injection: 2 mg/0.05 mL solution in a single-dose pre-filled syringe (3)
• Injection: 2 mg/0.05 mL solution in a single-dose vial (3)
Mechanism of Action: Vascular endothelial growth factor receptor (VEGFR) antagonist
Company: Regeneron Pharmaceuticals
+ Bayer
+ Santen Pharmaceutical
South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Eylea (aflibercept)” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Eylea (aflibercept) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
Contact Number:
M:+91-9891296838 / P:+91-11- 26532129
Email ID:
info@southdelhipharma.com
What Eylea is?
EYLEA is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with:
• Neovascular (Wet) Age-Related Macular Degeneration (AMD)
• Macular Edema Following Retinal Vein Occlusion (RVO)
• Diabetic Macular Edema (DME)
• Diabetic Retinopathy (DR)
What aflibercept is?
Aflibercept, sold under the brand names Eylea and Zaltrap, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. It was developed by Regeneron Pharmaceuticals and is approved in the United States and the European Union.
